A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Официальное название

A Phase 2, Open Label, Randomized Study of Neoadjuvant Dostarlimab Plus CAPEOX Versus CAPEOX in Participants With Previously Untreated T4N0 or Stage III MMRp/ MSS Colon Cancer

Обзор

The main goal of this study is to test a new treatment approach for colon cancer. The treatment involves dostarlimab along with a specific type of chemotherapy called CAPEOX (short for "capecitabine + oxaliplatin") to check if using these two together works better than using just CAPEOX by itself. This treatment is given before any surgery takes place; a method referred to as "neoadjuvant therapy." . The aim is to see if this new approach can show early signs of effectiveness in treating participants with a specific type of colon cancer known as mismatch repair proficient/ microsatellite stable (MMRp/MSS), where the cells have normal repair systems and stable DNA sequences. This study will also look at specific signs in the blood and tumor to see if they can help predict how well the treatment is working. This could help better understand how dostarlimab contributes to the response of the disease to treatment.

Вмешательства

• Биопрепарат Dostarlimab
  Dostarlimab will be administered.
• Препарат CAPEOX
  CAPEOX chemotherapy consisting of capecitabine and oxaliplatin will be administered.

Первичные конечные точки

• Major pathological response (mPR) rate [Срок оценки: Up to approximately 18 weeks]
• Number of participants with adverse events (AEs), serious adverse events (SAEs), immune-mediated adverse events (imAEs), and AEs leading to death or discontinuation of study intervention [Срок оценки: Up to approximately 105 weeks]

Вторичные конечные точки (5)

• Percentage of participants for whom primary tumour resection is not excluded [Срок оценки: Up to approximately 18 weeks]
• Complete pathologic response (cPR) rate [Срок оценки: Up to approximately 18 weeks]
• Major pathological response excluding cPR rate [Срок оценки: Up to approximately 18 weeks]
• Partial pathologic response rate [Срок оценки: Up to approximately 18 weeks]
• Negligible pathologic response rate [Срок оценки: Up to approximately 18 weeks]

Критерии участия

Критерии включения

• Has untreated pathologically confirmed colon adenocarcinoma
• Has resectable colon adenocarcinoma defined as clinically T4N0 or Stage III
• Has a tumor demonstrating the presence of either-

• MMR status: MMR status must be assessed by Immunohistochemistry (IHC) for MMR protein expression (MLH1, MSH2, MSH6, PMS2) where all proteins are present indicates MMRp; MMR status may be determined local laboratory; or
• MSS or Microsatellite Instability-L (MSI-L) phenotype as determined by polymerase chain reaction (PCR) or by tissue next generation sequencing (NGS), determined by local laboratory
• Provides fresh tumor tissue obtained during either the pre-screening or screening period via colonoscopy performed per procedure manual. Tissue biopsy is required
• Is willing to use adequate contraception male and/or female participants
• Has an Eastern Cooperative Oncology Group - Performance status (ECOG-PS) of 0 or 1
• Has adequate organ function

Критерии исключения

• Has distant metastatic disease
• Has received prior medical therapy (chemotherapy, immunotherapy, biologic, or targeted therapy), radiation therapy or surgery for management of colon cancer
• Has, in the investigator's opinion, a tumor that is not amenable to surgery or has any other contraindication to surgery
• Has experienced any of the following with prior immunotherapy: any imAE ≥ Grade 3, immune-mediated severe neurologic events of any-grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade \[Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), or Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome\], or myocarditis of any grade. Non-clinically significant laboratory abnormalities are not exclusionary
• Has any history of interstitial lung disease or immune-related pneumonitis
• Has a history or current evidence of any medical condition, therapy, or laboratory abnormality that might confound the study results, interfere with their participation for the full duration of the study intervention, or indicate it is not in the best interest of the participant to participate, in the opinion of the investigator
• Is considered, in investigator's opinion, a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease, or active infection requiring systemic therapy
• Has received treatment with an investigational agent within \[4 weeks\] of the first dose of study intervention
• Is pregnant or breastfeeding
• Has a history of severe allergic and/or anaphylactic reactions to chimeric, human, or humanized antibodies, fusion proteins, or known allergies to dostarlimab, or its excipients, or any components of CAPEOX

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Бельгия · 11 центров

• GSK Investigational Site — Aalst
• GSK Investigational Site — Bonheiden
• GSK Investigational Site — Brussels
• GSK Investigational Site — Brussels
• GSK Investigational Site — Ghent
• GSK Investigational Site — Leuven
• GSK Investigational Site — Liège
• GSK Investigational Site — Liège
• … и ещё 3 центра

Испания · 9 центров

• GSK Investigational Site — Barcelona
• GSK Investigational Site — Barcelona
• GSK Investigational Site — Barcelona
• GSK Investigational Site — Madrid
• GSK Investigational Site — Madrid
• GSK Investigational Site — Madrid
• GSK Investigational Site — Madrid
• GSK Investigational Site — Oviedo
• … и ещё 1 центр

Япония · 4 центра

• GSK Investigational Site — Osaka
• GSK Investigational Site — Osaka
• GSK Investigational Site — Tokyo
• GSK Investigational Site — Tokyo

Великобритания · 4 центра

• GSK Investigational Site — Glasgow
• GSK Investigational Site — Leeds West Yorkshire
• GSK Investigational Site — London
• GSK Investigational Site — Sutton

Италия · 3 центра

• GSK Investigational Site — Milan
• GSK Investigational Site — Roma
• GSK Investigational Site — Udine

Швейцария · 2 центра

• GSK Investigational Site — Bern
• GSK Investigational Site — Geneva

Идентификаторы

NCT: NCT06567782 · 222892 · 2024-513441-36

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗